Video

Techniques for Diagnosing Neuroendocrine Tumors

For High-Definition, Click

The diagnosis of neuroendocrine tumors comes with several inherent challenges, including the identification of type and primary site. To address this, several specialized imaging techniques are available, such as octreotide scans.

In general, Pamela L. Kunz, MD, notes that she generally begins with cross-sectional imaging using a multiphasic contrast-enhanced CT or MRI. She adds that as more data become available on novel therapeutics, the need to conduct an octreotide scan increases. Additionally, if more information is needed regarding the primary site of the tumor an octreotide scan may be required.

In many cases, several diagnostic tests are performed in an attempt to identify the primary site of the tumor, moderator Matthew H. Kulke, MD, points out. Rodney F. Pommier, MD, believes these efforts are completely necessary, as different treatments become available based on the type of tumor. In general, identifying the tumor type and primary site becomes more crucial, as new trials form and agents are approved.

Related Videos
Eunice S. Wang, MD
Marcella Ali Kaddoura, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Cedric Pobel, MD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine